Mazyar Shadman, MD, MPH

Mazyar Shadman, MD, MPH, is the Innovators Network Endowed Chair and an associate professor, in theClinical Research Division at Fred Hutchinson Cancer. He is also an associate professor in the Medical Oncology Division at University of Washington School of Medicine.

Articles

Dr Shadman on the Need for a Clinical Consensus in the Evolving Treatment Landscape of DLBCL

February 26th 2025

Mazyar Shadman, MD, MPH, discusses the need for a clinical consensus in selecting optimal treatment strategies in diffuse large B-cell lymphoma.

Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH

December 19th 2024

Dr Shadman discusses key findings and implications from trials that were presented at the 2024 ASH Annual Meeting investigating zanubrutinib in CLL.

Sustained Superiority of Zanubrutinib vs Bendamustine + Rituximab in Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN CLL): 5-Year Follow-Up of Cohort 1 from the SEQUOIA Study

December 18th 2024

Dr. Mazyar Shadman presents an OncLive Rapid Readout on the SEQUOIA study, highlighting 5-year follow-up data that confirm zanubrutinib’s sustained progression-free survival superiority over bendamustine plus rituximab in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma, with consistent efficacy across risk groups and a favorable long-term safety profile.

Dr Shadman on the Impact of Early Dose Reduction on Real-World Outcomes With Ibrutinib in CLL/SLL

August 28th 2024

Mazyar Shadman, MD, MPH, discusses real-world outcomes following early dose adjustments of first-line ibrutinib in CLL/SLL.

Dr Shadman on the Investigation of Sonrotoclax Combination Therapy in Treatment-Naive CLL

August 12th 2024

Mazyar Shadman, MD, MPH, discusses the investigation of sonrotoclax in the CELESTIAL-TNCLL trial in treatment-naïve chronic lymphocytic leukemia.

Future Treatment Directions and Ongoing Trials in CLL

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss ongoing trials and future treatment directions for chronic lymphocytic leukemia.

Real-World Safety Data for BTK Inhibitors in CLL from EHA 2024

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss real-world safety data for BTK inhibitors in chronic lymphocytic leukemia from EHA 2024.

Matching-Adjusted Indirect Comparisons of BTK Inhibitors in CLL

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss matching-adjusted indirect comparisons of BTK inhibitors in chronic lymphocytic leukemia.

The SEQUOIA Trial of Zanubrutinib vs BR in Previously Untreated CLL/SLL

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss findings from the SEQUOIA trial of zanubrutinib in treatment-naive chronic lymphocytic leukemia.

Translating BTK Inhibitor Data into Clinical Decision-Making

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss how to use data for BTK inhibitors to inform clinical decisions in chronic lymphocytic leukemia.

Factors for Selecting a BTK Inhibitor vs Other Regimens in CLL

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, on factors for selecting a BTK inhibitor or a venetoclax-based regimen in chronic lymphocytic leukemia.

Dr Shadman on the Evaluation of Zanbrutinib Plus Sonrotoclax in Treatment-Naive CLL

July 22nd 2024

Mazyar Shadman, MD, MPH, discusses the rationale for combining sonrotoclax plus zanubrutinib for treatment-naive chronic lymphocytic leukemia.

Comparative Efficacy of Bruton Tyrosine Kinase Inhibitors in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia: A Network Meta-Analysis

June 16th 2024

This is an evaluation of the results of a network meta-analysis covering the comparative efficacy of bruton tyrosine kinase Inhibitors in relapse/refractory chronic lymphocytic leukemia.

Dr Shadman on the Comparative Efficacy of Currently Available BTK Inhibitors in CLL

June 6th 2024

Mazyar Shadman, MD, MPH, discusses results from a network meta-analysis on the comparative efficacy of BTK inhibitors in relapsed/refractory CLL.

Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLL): A Matching-Adjusted Indirect Comparison (MAIC)

March 7th 2024

Mazyar Shadman, MD, MPH, presents data from a matching adjusted indirect comparison (MAIC) of the efficacy of zanubrutinib versus acalabrutinib in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) based on data from the Phase 3 ALPINE and Phase 3 ASCEND trials.

Dr Shadman on Zanubrutinib in CLL/SLL Intolerant to Prior BTK Inhibitors

October 8th 2023

Mazyar Shadman, MD, MPH, discusses preliminary long-term findings from the evaluation of zanubrutinib in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were intolerant to ibrutinib and/or acalabrutinib.

Dr. Shadman on the Efficacy and Safety of Zanubrutinib in CLL

September 7th 2023

Mazyar Shadman, MD, MPH, discusses the efficacy and safety of zanubrutinib in chronic lymphocytic leukemia, as well as data derived from the agents use which supports the regulatory approval of zanubrutinib in this patient population.

Dr. Shadman on the Exploration of the CAR T-Cell Therapy MB-106 in NHL/CLL

August 8th 2022

Mazyar Shadman, MD, MPH, discusses the exploration of MB-106, a third-generation CD20-targeted autologous CAR T-cell therapy, in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr. Shadman on the Efficacy of MB-106 in Relapsed/Refractory NHL and CLL

April 25th 2022

Mazyar Shadman, MD, MPH, discusses the efficacy of MB-106, a CD20-targeted CAR T-cell therapy in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr. Shadman on Methods Utilized to Evaluate MB-106 in B-NHL and CLL

January 12th 2022

Mazyar Shadman, MD, MPH, discusses the methods utilized in an ongoing phase 1/2 trial evaluating MB-106, an investigational CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.